BNT323/DB-1303

Phase 3Small molecule

BioNTech

BNT323/DB-1303 is one of 65 small molecule programs targeting Uterine Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Uterine CancerActive, not recruiting

Endometrial CancerRecruiting

Uterine CancerPhase 3

Active, not recruiting

Endometrial CancerPhase 3

Recruiting

Competition

Competitive Landscape

258 competitors in Endometrial Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

55 2

Keytruda

Merck & Co.

Phase 3

20 3

Femara

Novartis

Phase 3

19 4

Paraplatin

AAvyxa

Phase 3

38 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

26 6

Adriamycin

Pfizer

Phase 3

8 7

Lynparza

AstraZeneca

Phase 3

7 8

Lenvima

Eisai

Phase 3

6 9

Tecentriq

Roche

Phase 3

4 10

Trodelvy

Gilead

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 3Recruiting

Endometrial Cancer

NCT06340568

Clinical

Trials by Indication[1]

Endometrial Cancer1 trial

A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer

Recruiting· BioNTech logo

BioNTech·Phase 3·NCT06340568·480 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BNT323/DB-1303. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BNT323/DB-1303 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BNT323/DB-1303. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioNTech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BioNTech

BNT323/DB-1303

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Endometrial Cancer1 trial

References

Drug Info

Quick Facts

Related News